Format

Send to

Choose Destination
Eur J Cancer. 2019 Jan;107:8-14. doi: 10.1016/j.ejca.2018.11.009. Epub 2018 Dec 7.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

Author information

1
Department of Dermatology, University Hospital of Zürich, CH-8091, Zürich, Switzerland; Institute of Immunobiology, Kantonsspital St.Gallen, CH-9007, St. Gallen, Switzerland.
2
Institute of Immunobiology, Kantonsspital St.Gallen, CH-9007, St. Gallen, Switzerland.
3
Department of Oncology and Hematology, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland; Department of Oncology and Hematology, Hospital of Grabs, CH-9472, Grabs, Switzerland.
4
Department of Dermatology, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland.
5
Department of Oncology and Hematology, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland.
6
Research Group for Evolutionary Immunogenomics, Max Planck Institute for Evolutionary Biology, D-24306, Plön, Germany.
7
Department of Dermatology, University Hospital of Zürich, CH-8091, Zürich, Switzerland; Institute of Immunobiology, Kantonsspital St.Gallen, CH-9007, St. Gallen, Switzerland; Department of Oncology and Hematology, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland; Department of Dermatology, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland. Electronic address: lukas.flatz@kssg.ch.

Abstract

BACKGROUND:

Checkpoint inhibitors (CIs) are highly effective but can induce severe immune-related adverse events (irAEs), which cannot be predicted. We investigated whether human leukocyte antigen (HLA) genes predispose to developing of irAEs during therapy and thus hold a predictive role.

METHODS:

We established a prospective observational single-centre study and collected data from patients with either metastatic non-small cell lung cancer (NSCLC) or metastatic melanoma, who were treated with anti-PD-1 (programmed cell death receptor 1), anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) or both CIs combined. Data include irAEs and ranges from 15th July 2016 until 10th May 2018. In addition, we performed HLA typing via next generation sequencing.

RESULTS:

We enrolled 102 patients (median [range] age, 68 [62-74] years) with metastatic cancer in our study who received CI therapy. Of these patients, 59 (58%) developed one or more irAEs, among which pruritus (n = 32 (54%)) and rash (n = 24 (41%)) had the highest rates. We did not find evidence for a single HLA gene being associated with all irAEs (all P > .05). When assessing each irAE individually, we found a significant association between HLA-DRB1*11:01 and pruritus (OR = 4.53, X21,95 = 9.45, P < .01) as well as a nominally significant additive association between HLA-DQB1*03:01 and colitis (OR = 3.94, X21,95 = 5.67, P = .017).

CONCLUSIONS:

The presence of two HLA alleles that are known to predispose to autoimmune diseases were associated with the development of pruritus or colitis during therapy, suggesting a genetic aetiology of irAEs. Larger genome-wide association studies should be performed to confirm our findings.

KEYWORDS:

Cancer immunotherapy; Human leukocyte antigen; Immune-related adverse events; Melanoma; Non–small cell lung cancer; Therapeutic marker

PMID:
30529903
DOI:
10.1016/j.ejca.2018.11.009
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center